We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 30, 2021

Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine Among Older and Frail Patients With Advanced Gastroesophageal Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 May 13;[EPub Ahead of Print], PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, S Falk, J Wadsley, R Roy, T Tillett, J Nicoll, S Cummins, J Mano, S Grumett, Z Stokes, K Konstantinos-Velios, A Chatterjee, A Garcia, T Waddell, K Guptal, N Maisey, M Khan, J Dent, S Lord, A Crossley, E Katona, H Marshall, HI Grabsch, G Velikova, PL Ow, C Handforth, H Howard, MT Seymour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading